Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector

Gene Therapy

Volumn 17, Issue 10, 2010, Pages 1244-1252

  Becker, P S ^a   Taylor, J A ^b   Trobridge, G D ^a,c   Zhao, X ^a   Beard, B C ^c   Chien, S ^a   Adair, J ^c   Kohn, D B ^d   Wagner, J E ^e   Shimamura, A ^c,f   Kiem, H P ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

gene therapy; Hhypoxia; mitomycin C; reducing agent

Indexed keywords

ACETYLCYSTEINE; FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN SAFETY MODIFIED WOODCHUCK POST TRANSCRIPTIONAL REGULATORY ELEMENT; FANCONI ANEMIA GROUP A PROTEIN; FIBRONECTIN; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; LENTIVIRUS VECTOR; METHYLCELLULOSE; OXYGEN; PHOSPHOGLYCERATE KINASE; RECOMBINANT FIBRONECTIN PEPTIDE CH 296; STEM CELL FACTOR; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; FANCONI ANEMIA; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HYPOXIA; MONONUCLEAR CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION;

ACETYLCYSTEINE; BONE MARROW CELLS; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; LENTIVIRUS; MITOMYCIN; TRANSDUCTION, GENETIC;

LENTIVIRUS; MARMOTA MONAX;

EID: 77957988687     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.62     Document Type: Article

References (27)

1. Bagby GC, Alter BP. Fanconi anemia (Review). Semin Hematol 2006; 43: 147-156.
2. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress (Review). Blood 2006; 107: 4223-4233.
3. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins (Review). Nat Rev Genet 2007; 8: 735-748.
4. Liu JM, Kim S, Read EJ, Futaki M, Dokal I, Carter CS et al. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Hum Gene Ther 1999; 10: 2337-2346.
5. Yamada K, Olsen JC, Patel M, Rao KW, Walsh CE. Functional correction of fanconi anemia group C hematopoietic cells by the use of a novel lentiviral vector. Mol Ther 2001; 3: 485-490.
6. Yamada K, Ramezani A, Hawley RG, Ebell W, Arwert F, Arnold LW et al. Phenotype correction of Fanconi anemia group A hematopoietic stem cells using lentiviral vector. Mol Ther 2003; 8: 600-610.
7. Cohen-Haguenauer O, Peault B, Bauche C, Daniel MT, Casal I, Levy V et al. In vivo repopulation ability of genetically corrected bone marrow cells from Fanconi anemia patients. Proc Natl Acad Sci USA 2006; 103: 2340-2345.
8. Kelly PF, Radtke S, von Kalle C, Balcik B, Bohn K, Mueller R et al. Stem cell collection and gene transfer in Fanconi anemia. Mol Ther 2007; 15: 211-219.
9. Muller LU, Milsom MD, Kim MO, Schambach A, Schuesler T, Williams DA. Rapid lentiviral transduction preserves the engraftment potential of Fanca(\-/\-) hematopoietic stem cells. Mol Ther 2008; 16: 1154-1160.
10. Jacome A, Navarro S, Rio P, Yanez RM, Gonzalez-Murillo A, Lozano ML et al. Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients. Mol Ther 2009; 17: 1083-1092.
11. Butturini A, Gale RP, Verlander PC, Aldler-Bricner B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconi anemia: An International Fanconi Anemia Registry Study. Blood 1994; 84: 1650-1655.
12. Laufs S, Guenechea G, Gonzalez-Murillo A, Zsuzsanna Nagy K, Luz Lozano M, del Val C et al. Lentiviralvector integration sites in human NOD/SCID repopulating cells. J Gene Med 2006; 8: 1197-1207.
13. Beard BC, Keyser KA, Trobridge GD, Peterson LJ, Miller DG, Jacobs M et al. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, and foamy virus. Hum Gene Ther 2007; 18: 423-434.
14. Alter BP, Knobloch ME, Weinberg RS. Erythropoiesis in Fanconi's anemia. Blood 1991; 78: 602-608.
15. Waisfisz Q, Morgan NV, Savino M, de Winter JP, van Berkel CG, Hoatlin ME et al. Spontaneous functional correction of homo-zygous fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Nat Genet 1999; 22: 379-383.
16. Gregory Jr JJ, Wagner JE, Verlander PC, Levran O, Batish SD, Eide CR et al. Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci USA 2001; 98: 2532-2537.
17. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886-2892.
18. Kingsman SM, Mitrophanous K, Olsen JC. Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene Therapy 2005; 12: 3-4.
19. Levesque JP, Winkler IG, Hendy J, Williams B, Helwani F, Barbier V et al. Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow. Stem Cells 2007; 25: 1954-1965.
20. Shima H, Takubo K, Iwasaki H, Yoshihara H, Gomei Y, Hosokawa K et al. Reconstitution activity of hypoxic cultured human cord blood CD34-positive cells in NOG mice. Biochem Biophys Res Commun 2009; 378: 467-472.
21. Gross M, Hanenberg H, Lobitz S, Friedl R, Herterich S, Dietrich R et al. Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction. Cytogenet Genome Res 2002; 98: 126-135.
22. Mankad A, Taniguchi T, Cox B, Akkari Y, Rathbun RK, Lucas L et al. Natural gene therapy in monozygotic twins with Fanconi anemia. Blood 2006; 107: 3084-3090.
23. Zhang X, Shang X, Guo F, Murphy K, Kirby M, Kelley P et al. Defective homing is associated with altered Cdc42 activity in cells from patients with Fanconi anemia group A. Blood 2008; 112: 1683-1686.
24. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
25. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25: 217-222.
26. Yamashita T, Kupfer GM, Naf D, Suliman A, Joenje H, Asano S et al. The fanconi anemia pathway requires FAA phosphoryla-tion and FAA/FAC nuclear accumulation. Proc Natl Acad Sci USA 1998; 95: 13085-13090. (Pubitemid 28509528)
27. Beard BC, Sud R, Keyser KA, Ironside C, Neff T, Gerull S et al. Long-term polyclonal and multilineage engraftment of methylguanine methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients. Blood 2009; 113: 5094-5103.